Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?
Proton-pump inhibitors (PPIs) can alter the pharmacodynamic profile of clopidogrel and reduce its platelet-inhibitory effects. Ho and colleagues have reported that concurrent use of PPIs and clopidogrel leads to in an increase in adverse cardiovascular outcomes. In this article we discuss the clinical implications of the interaction between these two drugs.
Ferreiro
José Luis
JL
Angiolillo
Dominick J
DJ
D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D000077144:Clopidogrel; D004347:Drug Interactions; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D055502:Secondary Prevention; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine